BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Eris Lifesciences Ltd. delivered better than expected Q2 FY23 performance, led by superior traction in new launches and improved operating leverage.
Eris is not only sustaining the momentum in its recently launched products, but it is also preparing itself for an aggressive pace of new introductions.
We remain positive on Eris on the back of-
exciting product pipeline over the next three years, led by patent expiration,
enhancing anti-diabetes portfolio,
diversifying into therapies such as dermatology, cosmetology, central nervous system and women health.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR